Camurus AB operates as a research based pharmaceutical company. The company is headquartered in Lund, Skane and currently employs 285 full-time employees. The company went IPO on 2015-12-03. The firm has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
최신 재무제표(Form-10K)에 따르면, Camurus AB (publ)의 총 자산은 $4,739이며, 순이익입니다.
CAMRF의 주요 재무 비율은 무엇인가요?
Camurus AB (publ)의 유동비율은 9.4이고, 순이익률은 32.45, 주당 매출은 $38.23입니다.
Camurus AB (publ)의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Camurus AB (publ) 주요 수익원은 Sales of Development Related Goods and Services이며, 최신 수익 발표에서 수익은 2,252,000입니다. 지역별로는 Sweden이 Camurus AB (publ)의 주요 시장이며, 수익은 117,170,000입니다.